Abstract 3753
Background
The advanced practice nurse (APN), with ability to apply evidence in an integrated framework, assumes new roles and acts as benchmark for patient and other professionals. In the last two decades, nurses have developed new advanced roles. There is international experience of the implementation for new model, and organizational ways by integrating and integrate interventions for EPA. High positive results in coordinating services and multidisciplinary teams, facilitate continuity of care resulting better quality of life and greater satisfaction for patients.
Methods
Descriptive study with patients treated in the functional unit of the Catalan Institute of Oncology in year 2018. After literature review on roles for nurses in lung cancer, we review number of interventions and activity carried out by EPA.
Results
A total of 589 first cases lung cancer started their first treatment. Nurse visited 93.2% of them in the Lung Functional Unit (LFU). Type of treatment; surgical 26.41%, palliative chemotherapy 11.83%, concomitant chemo+ radiotherapy in 11.65%, immunotherapy 4.19%, TKis 3.1%, sequential chemo+radiotherapy 3.2%, neoadjuvant chemo 1.58%, chemo+immunotherapy 0.27%, neoadjuvant chemo+radiotherapy+surgery in 0.15% and the rest 37.62% with supportive or palliative treatment. A total of 2563 visits by nurse, 21.42% were first visits, 73.23% patients with active treatment and 4.7% that have completed the treatment but with some toxicity. A total of 3935 phone calls were attended by nurses, of which 81.19% were patients who made calls and 18.80% were nurses on phone for control. Derivation was resulting to emergency for 5.13% of patients. 87.79% cases presented in Lung tumors board needed coordination for visits and for complementary proves.
Conclusions
Incorporate the EPA in the multidisciplinary care helps to minimize complications, to improve coordination and avoid deviations of the care process. Key activities were: health education to patient and family on care and self-care, improve the compression of the disease, the treatment and the process, strengthen information, minimize problems and improve resources for the care process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract